{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:44:23Z","timestamp":1787726663159,"version":"build-2784847793"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Carbapenem-resistant Acinetobacter baumannii (CRAB) is characterized as a critical priority pathogen with restricted therapeutic options. To date, the most effective antimicrobial treatment against this difficult-to-treat bacterial strain has not been established. Sulbactam is a \u03b2-lactamase inhibitor with intrinsic activity against this pathogen, however, as a \u03b2-lactam, it can be hydrolysed by \u03b2-lactamases produced by A. baumannii. High-dose, extended-infusion treatment with sulbactam can overcome this hydrolysis by \u03b2-lactamases and is considered an effective therapeutic strategy against CRAB. The aim of this review is to analyse primary and secondary research studies that compare sulbactam-based with other regimens, such as polymyxin-containing regimens, tigecycline-containing regimens and other antimicrobial combinations against CRAB infections, especially ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP) and bacteraemia. Our findings suggest that results are conflicting, mostly because of high heterogeneity among studies. However, in most studies, sulbactam-based regimens have demonstrated comparable, and in several studies more favourable results in contrast to other antimicrobial treatments with respect to clinical cure and mortality in CRAB-associated pneumonia, yet without reaching statistical significance in most cases. The auspicious novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination sulbactam\/durlobactam is also discussed, although real-world clinical data regarding its efficacy in CRAB infections are still scarce. More randomized controlled trials comparing sulbactam-based with other regimens are warranted to determine the most effective antimicrobial combination against CRAB infections. Nevertheless, current data suggest that sulbactam could play a major role in this combination treatment.<\/jats:p>","DOI":"10.1093\/jacamr\/dlaf055","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:00:16Z","timestamp":1744452016000},"source":"Crossref","is-referenced-by-count":13,"title":["Sulbactam for carbapenem-resistant <i>Acinetobacter baumannii<\/i> infections: a literature review"],"prefix":"10.1093","volume":"7","author":[{"given":"Nikolaos","family":"Spernovasilis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, German Medical Institute , 4108 Limassol ,","place":["Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ishak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital , 48202 Detroit, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-8529","authenticated-orcid":false,"given":"Constantinos","family":"Tsioutis","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus , 2404 Nicosia ,","place":["Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Alon-Ellenbogen","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Sciences, University of Nicosia , 2417 Nicosia ,","place":["Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris P","family":"Agouridis","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus , 2404 Nicosia ,","place":["Cyprus"]},{"name":"Department of Internal Medicine, German Medical Institute , 4108 Limassol ,","place":["Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Mazonakis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thoracic Diseases General Hospital Sotiria , 11527 Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"2025042905362667000_dlaf055-B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2025042905362667000_dlaf055-B2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3389\/fmicb.2019.01601","article-title":"The mechanisms of disease caused by Acinetobacter baumannii","volume":"10","author":"Morris","year":"2019","journal-title":"Front Microbiol"},{"key":"2025042905362667000_dlaf055-B3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: the most critical pathogens","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"key":"2025042905362667000_dlaf055-B4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2025042905362667000_dlaf055-B5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00134-020-05929-3","article-title":"Antimicrobial-associated harm in critical care: a narrative review","volume":"46","author":"Arulkumaran","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025042905362667000_dlaf055-B6","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1128\/AAC.01464-06","article-title":"Global challenge of multidrug-resistant Acinetobacter baumannii","volume":"51","author":"Perez","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/antibiotics10111344","article-title":"Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii","volume":"10","author":"Karakonstantis","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025042905362667000_dlaf055-B8","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025042905362667000_dlaf055-B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025042905362667000_dlaf055-B10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B11","doi-asserted-by":"publisher","first-page":"e01612-17","DOI":"10.1128\/AAC.01612-17","article-title":"Kinetics of sulbactam hydrolysis by \u03b2-lactamases, and kinetics of \u03b2-lactamase inhibition by sulbactam","volume":"61","author":"Shapiro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B12","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025042905362667000_dlaf055-B13","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1093\/jac\/dku179","article-title":"Characterization of plasmids carrying the blaOXA-24\/40 carbapenemase gene and the genes encoding the AbkA\/AbkB proteins of a toxin\/antitoxin system","volume":"69","author":"Mosqueda","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jac\/dkp428","article-title":"Global spread of carbapenem-resistant Acinetobacter baumannii","volume":"65","author":"Higgins","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B15","doi-asserted-by":"publisher","first-page":"e0226023","DOI":"10.1128\/mbio.02260-23","article-title":"A global view on carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"M\u00fcller","year":"2023","journal-title":"mBio"},{"key":"2025042905362667000_dlaf055-B16","doi-asserted-by":"publisher","first-page":"104940","DOI":"10.1016\/j.ejps.2019.05.018","article-title":"Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii","volume":"136","author":"Jaruratanasirikul","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 6","key":"2025042905362667000_dlaf055-B17","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1093\/cid\/ciu706","article-title":"Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025042905362667000_dlaf055-B18","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1128\/AAC.00342-13","article-title":"Pharmacodynamics modeling to optimize dosage regimens of sulbactam","volume":"57","author":"Jaruratanasirikul","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B19","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.33.9.1470","article-title":"Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis","volume":"33","author":"Blum","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.32.4.503","article-title":"Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis","volume":"32","author":"Reitberg","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2215\/CJN.05690611","article-title":"Pharmacokinetics of ampicillin\/sulbactam in critically Ill patients with acute kidney injury undergoing extended dialysis","volume":"7","author":"Lorenzen","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042905362667000_dlaf055-B22","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1248\/bpb.b15-00334","article-title":"Pharmacokinetics of prophylactic ampicillin\u2013sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass","volume":"38","author":"Yokoyama","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2025042905362667000_dlaf055-B23","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat Microbiol"},{"key":"2025042905362667000_dlaf055-B24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1099\/jmm.0.001211","article-title":"In vitro synergistic activity of the sulbactam\/avibactam combination against extensively drug-resistant Acinetobacter baumannii","volume":"69","author":"Rodriguez","year":"2020","journal-title":"J Med Microbiol"},{"key":"2025042905362667000_dlaf055-B25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/antibiotics10050577","article-title":"A new twist: the combination of sulbactam\/avibactam enhances sulbactam activity against carbapenem-resistant Acinetobacter baumannii (CRAB) isolates","volume":"10","author":"Pasteran","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025042905362667000_dlaf055-B26","doi-asserted-by":"publisher","first-page":"dlae203","DOI":"10.1093\/jacamr\/dlae203","article-title":"Pharmacokinetic\/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid","volume":"6","author":"Abouelhassan","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2025042905362667000_dlaf055-B27","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1093\/jac\/dkv267","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2025042905362667000_dlaf055-B29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025042905362667000_dlaf055-B30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"2025042905362667000_dlaf055-B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","article-title":"Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"42","author":"Kalin","year":"2014","journal-title":"Infection"},{"key":"2025042905362667000_dlaf055-B32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025042905362667000_dlaf055-B33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2025042905362667000_dlaf055-B34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijantimicag.2014.01.016","article-title":"Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia","volume":"43","author":"Khawcharoenporn","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025042905362667000_dlaf055-B35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-013-1870-4","article-title":"Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections","volume":"32","author":"Lee","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025042905362667000_dlaf055-B36","doi-asserted-by":"publisher","first-page":"908.e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025042905362667000_dlaf055-B37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.29271\/jcpsp.2020.03.332","article-title":"Effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant Acinetobacter baumannii pulmonary infection","volume":"30","author":"Lv","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025042905362667000_dlaf055-B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"2025042905362667000_dlaf055-B39","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran J Pharm Res"},{"key":"2025042905362667000_dlaf055-B40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13756-019-0502-x","article-title":"Comparison of tigecycline or cefoperazone\/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii","volume":"8","author":"Niu","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025042905362667000_dlaf055-B41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/jac\/dkn128","article-title":"Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp","volume":"61","author":"Oliveira","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.22037\/ijpr.2019.112466.13775","article-title":"Comparison of intravenous ampicillin-sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant Acinetobacter baumannii: randomized open label trial","volume":"18","author":"Pourheidar","year":"2019","journal-title":"Iran J Pharm Res"},{"key":"2025042905362667000_dlaf055-B43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5414\/CP203102","article-title":"Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii","volume":"56","author":"Qin","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025042905362667000_dlaf055-B44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jgar.2021.01.018","article-title":"What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea","volume":"24","author":"Seok","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025042905362667000_dlaf055-B45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-016-1717-6","article-title":"Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"16","author":"Ye","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025042905362667000_dlaf055-B46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"2025042905362667000_dlaf055-B47","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Ther"},{"key":"2025042905362667000_dlaf055-B48","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.2147\/IDR.S225518","article-title":"Clinical outcomes of colistin in combination with either 6-G sulbactam or carbapenems for the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam, a prospective cohort study","volume":"12","author":"Ungthammakhun","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2025042905362667000_dlaf055-B49","doi-asserted-by":"publisher","first-page":"106271","DOI":"10.1016\/j.ijantimicag.2020.106271","article-title":"Enhanced bacterial killing with colistin\/sulbactam combination against carbapenem-resistant Acinetobacter baumannii","volume":"57","author":"Bian","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2025042905362667000_dlaf055-B50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"De Pascale","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2025042905362667000_dlaf055-B51","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"2025042905362667000_dlaf055-B52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"key":"2025042905362667000_dlaf055-B53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bjid.2012.10.029","article-title":"Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis","volume":"17","author":"Chu","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"2025042905362667000_dlaf055-B54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025042905362667000_dlaf055-B56","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2025042905362667000_dlaf055-B57","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"El-Ghali","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025042905362667000_dlaf055-B58","doi-asserted-by":"publisher","first-page":"e01506-19","DOI":"10.1128\/AAC.01506-19","article-title":"Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis","volume":"64","author":"Sagan","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B59","doi-asserted-by":"publisher","first-page":"e01627-24","DOI":"10.1128\/aac.01627-24","article-title":"A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp","volume":"69","author":"Veeraraghavan","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B60","doi-asserted-by":"publisher","first-page":"e0092421","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042905362667000_dlaf055-B61","doi-asserted-by":"publisher","first-page":"ofac092","DOI":"10.1093\/ofid\/ofac092","article-title":"Novel combination therapy for extensively drug-resistant Acinetobacter baumannii necrotizing pneumonia complicated by empyema: a case report","volume":"9","author":"Holger","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025042905362667000_dlaf055-B62","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cid\/ciae210","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025042905362667000_dlaf055-B63","doi-asserted-by":"publisher","first-page":"1381123","DOI":"10.3389\/fmed.2024.1381123","article-title":"Case report: successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy","volume":"11","author":"Snowdin","year":"2024","journal-title":"Front Med"},{"key":"2025042905362667000_dlaf055-B64","doi-asserted-by":"publisher","first-page":"dlad078","DOI":"10.1093\/jacamr\/dlad078","article-title":"Salvage therapy with sulbactam\/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization","volume":"5","author":"Tiseo","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2025042905362667000_dlaf055-B65","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/cells13161315","article-title":"Synergistic activity of cefiderocol in combination with avibactam, sulbactam or tazobactam against carbapenem-resistant Gram-negative bacteria","volume":"13","author":"Lewis","year":"2024","journal-title":"Cells"},{"key":"2025042905362667000_dlaf055-B66","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jac\/dkad032","article-title":"In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii","volume":"78","author":"Gill","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025042905362667000_dlaf055-B67","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d Gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf055\/62918783\/dlaf055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf055\/62918783\/dlaf055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:36:35Z","timestamp":1745919395000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf055\/8112107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf055","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,4]]},"article-number":"dlaf055"}}